Mendoza v. Procter & Gamble Co., No. CV 23-1382-DMG (JPRx), 2023 WL 8860900 (C.D. Cal. Dec. 20, 2023)
Mendoza brought the usual
California claims, alleging that Vicks Vapo cough and cold treatment
products marketed as being for children were identical to the adult versions,
only pricier; the court mostly rejected P&G’s motion to dismiss. The
Children’s VapoRub front label states that it is for children two and older;
the Standard Product’s front label includes no age instruction. Id. ¶
Children’s VapoRub costs approximately $1.03 more per ounce than Standard
VapoRub. The Children’s VapoPatch includes a picture of a cartoon child wearing
the patch; the Standard Product contains a more defined image of an adult
wearing the patch, and costs at least $0.70 less. The Children’s VapoCream
includes the language “easy to apply” and illustrations of various objects,
such as an airplane, butterfly, flowers, stars, paper airplanes, and clouds;
the Standard Product does not have such language or illustrations and costs
less.
There was no FDCA preemption of a standard misleadingness claim.
Further, the complaint sufficiently alleged an affirmative misrepresentation
that led reasonable consumers to believe, falsely, that the products were
specially formulated for children—not just a price differential. Negligent
misrepresentation claims failed, however, for want of non-economic damages.
Mendoza had standing to challenge the VapoCream products
because the products and alleged misrepresentations were sufficiently similar
to those of the products she did buy. And she sufficiently alleged that she
“would like to, and would consider, purchasing the Products again ... [but]
will be unable to rely on the Products’ advertising or labeling in the future,
and so will not purchase the Products again although she would like to” to have
standing for injunctive relief.
No comments:
Post a Comment